Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGK1 | O00141 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30791216 | 1.00 | SGK1 (0.33) | SGK1GRM4KDRPDGFRB | |
| SCHEMBL23356121 | 0.85 | EGFR (0.43) | SGK1KDR | |
| SCHEMBL30791233 | 0.85 | EGFR (0.43) | SGK1KDR | |
| SCHEMBL30791205 | 0.84 | GRM4 (0.31) | SGK1GRM4PDGFRB | |
| SCHEMBL23356067 | 0.84 | GRM4 (0.31) | SGK1GRM4PDGFRB | |
| SCHEMBL23356075 | 0.82 | GRM4 (0.35) | SGK1GRM4 | |
| SCHEMBL30791203 | 0.82 | GRM4 (0.35) | SGK1GRM4 | |
| SCHEMBL30791202 | 0.79 | TRPA1 (0.32) | SGK1KDRPDGFRB | |
| SCHEMBL23356066 | 0.79 | TRPA1 (0.32) | SGK1KDRPDGFRB | |
| SCHEMBL23356058 | 0.79 | EGFR (0.35) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583852-B2 | Heterocycle derivative | JW PHARMACEUTICAL CORPORATION (KR) | 2026-03-24 | — | — | US | disclosed |
| CN-112313232-B | Novel heterocyclic derivatives | JW中外制药公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | JW PHARMACEUTICAL CORPORATION (KR) | 2022-08-18 | — | — | US | disclosed |
| EP-3822270-A1 | NOVEL HETEROCYCLE DERIVATIVE | JW Pharmaceutical Corporation (KR) | 2021-05-19 | — | — | EP | disclosed |
| CN-112313232-A | Novel heterocyclic derivatives | JW中外制药公司 | 2021-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583852-B2 | Heterocycle derivative | AR, SRD5A1, NR5A1 | SGK1 839/4885GRM4 3902/4885KDR 4174/4885 |
| US-20220259199-A1 | NOVEL HETEROCYCLE DERIVATIVE | AR, BRDT, NR5A1 | SGK1 497/4885GRM4 3993/4885KDR 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.